Drugs / tgAAC94
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00617032 Comparator | Feb 2004 → Nov 2005 | rheumatoid arthritis | Targeted Genetics Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT00126724 Comparator | Aug 2005 → Oct 2008 | ankylosing spondylitis, psoriatic arthritis | Targeted Genetics Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tgAAC94 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00126724 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “tgAAC94 is a recombinant adeno-associated virus serotype 2 (AAV2) vector genetically engineered” NCT00126724 ↗ |
| Route | Other | “Intra-articular delivery of the TNFR:Fc gene (tgAAC94)” NCT00126724 ↗ |